GlassScriptPhysician profile
Ross Tanis
NPI 1861951949
$3,530.33
in general payments reported to CMS, 2019-2025
21 companies · $2,531 in 2025
The $2,531 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $33.60 · 2024: $857 · 2025: $2,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,348 · Education: $73.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.46 |
| Education | $73.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $765.42 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $469.03 | 2022-2025 | Airsupra, Tezspire |
| Csl Behring | $419.05 | 2024-2025 | Andembry, Hizentra, Haegarda |
| Genzyme Corporation | $269.90 | 2024-2025 | |
| Glaxosmithkline, LLC. | $248.37 | 2024-2025 | Nucala |
| Blueprint Medicines Corporation | $230.80 | 2024-2025 | Ayvakit |
| Pfizer INC. | $215.59 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $199.40 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.18 | 2024-2025 | Cuvitru, Takhzyro, Eohilia |
| Genentech USA, INC. | $121.29 | 2024-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $113.83 | 2025 | Neffy |
| Octapharma USA, INC. | $59.13 | 2024 | Panzyga |
| Amgen INC. | $50.36 | 2024-2025 | Actimmune, Tezspire |
| Biocryst US Sales Co., LLC | $46.94 | 2025 | Orladeyo |
| Pharming Healthcare, INC. | $28.96 | 2024 | Ruconest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $25.67 | 2024 | Opzelura |
| Abbvie INC. | $24.70 | 2025 | |
| Lilly USA, LLC | $24.20 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $22.52 | 2025 | Ryaltris |
| Greer Laboratories, INC. | $19.86 | 2025 | Oralair |
| Kaleo, INC. | $18.13 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Tanis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.